Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Harvard scientists track what happens inside your body after eating

NCT ID NCT05616585

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study from Harvard University aimed to find biological markers in urine, blood, and stool that change after eating specific foods. Researchers gave 115 healthy adults controlled meals and measured hundreds of compounds to better understand how the body processes food. The goal is to improve how we track diet and nutrition in future studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

115 people

The number who actually took part.

Started

Feb 2023

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy adults Men and women, 18+ * Body Mass Index (BMI) 18.5-39.9 kg/m2 * Willingness to participate in all study visits Exclusion Criteria: * History of gastrointestinal conditions (e.g., ulcerative colitis, Crohn disease, celiac sprue, Hereditary Non-polyposis Colorectal Cancer, familial adenomatous polyposis, pancreatic disease, liver disease) * Bleeding disorders that preclude blood draws * Anemia- as self-reported in the Screening Questionnaire * Previous gastrointestinal resection or gastric bypass surgery * Recent hospital admissions (in past 6 months) for heart disease (myocardial infarction, cerebrovascular accident, or congestive heart failure) or other cerebrovascular/ coronary artery disease condition under physician guided therapy that is not medically stable. * Cancer under radiation or chemotherapy treatment that is active or within 6 months of treatment. Except for non-melanoma skin cancer. * Women who are pregnant or lactating * Weight change (±5% in3 months) * Regular alcohol intake of \>2 drinks/day (2 drinks being equivalent to 720 ml beer, 240 ml wine, or 90 ml spirits) and unwilling to abstain during feeding periods * Use of tobacco, marijuana, hookahs, vape, or e-cigarettes and not willing to abstain during feeding periods. * Use of illicit drugs and not willing abstain during feeding periods. * Body mass index \>40 kg/m2 * Hypertension- seated blood pressure \>140 mmHg or diastolic \>90 mmHg * Food allergies/intolerances or major dislikes to foods used in the study menus; unwilling to consume study foods. * Regular (daily to weekly) use of over-the-counter weight-loss aids, anti-inflammatories, and unwilling to stop taking these during feeding periods * Unwilling to stop taking over the counter dietary supplements that interfere with the test foods being studied, including pills, chewable, liquids or powders for the following: protein supplements, soy, fiber, flaxseed, fish oil (incl. cod liver oil), probiotics, carotenoids, selenium, other antioxidants, other phytochemicals, glucosamine, and chondroitin. If vitamin supplement is MD prescribed, the participant may be enrolled subject to the investigator's judgment. Staff will review supplement to determine eligibility. * Oral or IV antibiotic use in the past 3 months (could defer participation until 3 months post completion of course of antibiotics) * Inability to freely give informed consent * Clinical lab tests outside acceptable value as ascertained at a screening blood draw and current use of specific prescription medications per self-report Description \[Acceptable Values\] Glucose-Fasting: Serum Glucose \[54-125 mg/dl\] Blood Urea Nitrogen \[6-50mg/dl\] Serum Creatinine \[0.4-1.3 mg/dl\] Estimated glomerular filtration rate (eGFR) \[\>60ml/min\] Serum Sodium \[133-146 mmol/L\] Alanine Aminotransferase/glutamate-pyruvate transaminase (ALT/GPT) Liver Enzyme \[5-60 U/L\] Aspartate aminotransferase (AST/GOT) Liver Enzyme \[5-40 U/L\] Alkaline Phosphatase Liver Enzyme \[20-135 U/L\] Total Bilirubin Liver Function \[0.0-1.9 mg/dl\] Total Serum Protein \[5-9.0 g/dl\] Albumin Serum Protein \[3.5-5.9 g/dl\] LDL Cholesterol \[\<160 mg/dl\] Triglycerides \[\<500 mg/dl\] White Blood Cells (WBC) \[3-10.5 K/per microliter (μL)\] Hematocrit (HCT) (women) \[35-48 g/dl\] Hematocrit (HCT) (men) \[37.5-49 g/dl\] Prescription Medications that would Exclude Participation: * Diuretics * Steroids (oral): daily oral any dose within 1 month of study, except as noted below * Nonsteroidal anti-inflammatory drugs (NSAIDS): when prescribed for treatment or is regularly consumed (i.e.. Daily), or can't be stopped for 2 days without pain, except 81 mg Aspirin * Opiates: any use within 1 month of study * Antilipemic Agents that affect GI or renal function (i.e.. Fibrates) * Antidiabetics and Hypoglycemic medications other than metformin (i.e.. insulin, SGLT2 inhibitor, α-glucosidase inhibitor) * Psychiatric that affect metabolism/renal function (anti-psychotics, lithium) * Biologics/immune modulators (i.e.. rheumatoid arthritis (RA), psoriasis, other rheumatologic/hematologic active disease) * Anti-coagulants (coumadin, heparin, Eliquis, etc.) * Human immunodeficiency virus (HIV) or highly active antiretroviral therapy (HAART) , etc. * Medications that are approved: Steroids (nasal or topical), Aspirin, NSAIDS and Tylenol (avoid day before and day of study visit, Statins, Metformin, Psychiatric drugs other than anti-psychotics (SSRI, tricyclics, benzo), oral contraception pill (OCP)/Hormonal Replacement Therapy (HRT), Tobacco cessation products (patches/lozenge), Oral contraceptives, Gender- affirming HRT, Testosterone for hypogonadal males.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biological markers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mass General Brigham Center for Clinical Investigation

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.